New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Oncternal Therapeutics, Inc.
ONCT
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

2M

Biotechnology

Next Earning date - 06 Mar 2025

2M

Biotechnology

Next Earning date - 06 Mar 2025

0.53USD

Shape-0.17 ( -24.12%)
Market Closed (as of Dec 02, 21:00 EDT)
favorite-chart

Relative Strenght

2
favorite-chart

Volume Buzz

934%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

95%

Quote Panel

Shape
Updated February 11, 2025
1W % 1M % 3M -56.48 % 1Y -94.57 %

Key Metrics

Shape
  • Market Cap

    1.56M


  • Shares Outstanding

    2.96M


  • Share in Float

    2.71M


  • Dividende

    0


  • Earning Date

    06 Mar 2025


  • Price Target

    0.5266


  • Average Volume

    62268


  • Beta

    1.358


  • Range

    0.5266-10.613


  • Industry

    Biotechnology


  • Website

    https://www.oncternal.com


  • Sector

    Healthcare


Fundamentals

Shape

Relative Strength

Shape

ONCT

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$600K

ShapeNaN%

2025-Revenue

$10.25

Shape-258%

2025-EPS

$360K

Shape96%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

0.00(-100.00%)

Number of analyst

0

Last analyst upgrade/downgrade

Brookline Capital

upgrade

Previous: Not converted

2023-12-04

Now: Buy

H.C. Wainwright

upgrade

Previous: Not converted

2023-09-18

Now: Buy

Cantor Fitzgerald

initialise

Previous: Not converted

2022-12-22

Now: Overweight

BTIG

initialise

Previous: Not converted

2022-02-24

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

N/A

-4.00
vs -3.20

Q1.23

arrow
arrow

N/A

-4.00
vs -4.00

Q2.23

arrow
arrow

N/A

-3.00
vs -4.60

Q3.23

arrow
arrow

N/A

-3.40
vs -4.20

Q4.23

arrow
arrow

N/A

-3.11
vs -4.00

Q1.24

arrow
arrow

N/A

-2.83
vs -4.00

Q2.24

arrow
arrow

N/A

-2.89
vs -3.00

Q3.24

arrow
arrow

N/A

-2.86
vs -3.40

Q4.24

arrow
arrow

N/A

-3.47
vs -3.11

Q1.25

arrow
arrow

N/A

-2.29
vs -2.83

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

-69%

171K  vs 556K

Q1.23

arrow
arrow

-73%

203K  vs 746K

Q2.23

arrow
arrow

-44%

106K  vs 191K

Q3.23

arrow
arrow

-53%

179K  vs 382K

Q4.23

arrow
arrow

+74%

297K  vs 171K

Q1.24

arrow
arrow

+180%

569K  vs 203K

Q2.24

arrow
arrow

+656%

801K  vs 106K

Q3.24

arrow
arrow

-100%

NA  vs 179K

Q4.24

arrow
arrow

-7%

275K  vs 297K

Q1.25

arrow
arrow

-65%

200K  vs 569K

Return on EquityShape

status-upQoQ

Q4.22

arrow
arrow

+7%

0.07
vs -0.16

Q1.23

arrow
arrow

-22%

-0.22
vs 0.07

Q2.23

arrow
arrow

+5%

0.05
vs -0.22

Q3.23

arrow
arrow

+5%

0.05
vs 0.05

Q4.23

arrow
arrow

-30%

-0.30
vs 0.05

Q1.24

arrow
arrow

-37%

-0.37
vs -0.30

Q2.24

arrow
arrow

-54%

-0.54
vs -0.37

Q3.24

arrow
arrow

-93%

-0.93
vs -0.54

Institutionnal OwnershipShape

status-upQoQ

Q1.22

arrow
arrow

80

80
vs 85

-6%

Q2.22

arrow
arrow

70

70
vs 80

-12%

Q3.22

arrow
arrow

56

56
vs 70

-20%

Q4.22

arrow
arrow

60

60
vs 56

7%

Q1.23

arrow
arrow

54

54
vs 60

-10%

Q2.23

arrow
arrow

53

53
vs 54

-2%

Q3.23

arrow
arrow

51

51
vs 53

-4%

Q4.23

arrow
arrow

37

37
vs 51

-27%

Earnings Growth

Latest News